Long-Term Follow-up of AF-001JP: A Phase I/II Study of Alectinib in ALK-Positive NSCLC
09:42 Share

Podcast re: 'Three-year Follow-up of an Alectinib Phase 1/2 Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP' by Tamura et al.